Brain and Mind Centre, The University of Sydney, Sydney, Australia.
Prince of Wales Clinical School, The University of New South Wales, Sydney, Australia.
Expert Rev Neurother. 2020 Mar;20(3):281-293. doi: 10.1080/14737175.2020.1727740. Epub 2020 Feb 14.
: A spectrum of non-motor manifestations in amyotrophic lateral sclerosis (ALS) patients has been increasingly recognized, with cognitive and behavioral impairments the most prominent. Evidence suggests that ALS overlaps on a pathological, genetic, and clinical level with frontotemporal dementia (FTD), thereby suggesting a frontotemporal spectrum disorder (ALS-FTSD). Cognitive impairment has been reported in up to 75% of ALS patients, whilst the rate of behavioral dysfunction ranges up to 50%.: The present review explores the current understanding of cognitive and behavioral changes in ALS with a particular emphasis on its implications on prognosis and survival.: Further longitudinal studies are needed to clarify the evolution of cognitive impairment in ALS and how this may ultimately influence survival. Improving understanding of cognitive changes has important implications toward the capacity of patients in making critical medical decisions. There is a need to develop a universally accepted and validated cognitive assessment tool to be administered in a multidisciplinary clinic that is efficient and sensitive, as well as being integrated into the design and analysis of future ALS drug trials. In addition, revision of the ALS diagnostic criteria is critically needed that should accommodate cognitive and behavioral symptoms in addition to motor manifestations.
肌萎缩侧索硬化症(ALS)患者的非运动症状谱逐渐被认识到,认知和行为障碍最为突出。有证据表明,ALS 在病理、遗传和临床层面上与额颞叶痴呆(FTD)重叠,因此提示存在额颞叶功能障碍谱障碍(ALS-FTSD)。高达 75%的 ALS 患者存在认知障碍,而行为功能障碍的发生率高达 50%。本文综述探讨了 ALS 认知和行为变化的现有认识,特别强调了其对预后和生存的影响。需要进一步的纵向研究来阐明 ALS 中认知障碍的演变,以及这最终如何影响生存。提高对认知变化的理解对患者做出关键医疗决策的能力具有重要意义。需要开发一种通用的、经过验证的认知评估工具,在多学科诊所中进行管理,该工具应具有高效、敏感的特点,并整合到未来 ALS 药物试验的设计和分析中。此外,还迫切需要修订 ALS 诊断标准,使其能够适应运动表现之外的认知和行为症状。